{"schema_version":"secwatch.filing_event.v1","accession":"0001387131-23-006126","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2023-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.839521+00:00","generated_at":"2026-06-15T12:42:29.172132+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Tonix Q1 net loss $33M, cash $72M; Phase 3 TNX-102 SL topline due Q4 2023","bullets":["Net loss $33.0M ($0.52 per share) vs $26.4M ($1.61) in Q1 2022; cash $72.0M at Mar 31, 2023, down from $120.2M at Dec 31, 2022.","R&D expenses $26.5M (up from $18.4M) due to advancing clinical programs; G&A decreased to $7.4M from $8.0M.","Cash used in operations $32.9M vs $31.0M; share repurchase of 16.7M shares at $0.82 avg for $13.6M.","Pipeline: TNX-102 SL Phase 3 RESILIENT topline expected Q4 2023; TNX-601 ER Phase 2 enrolling; TNX-1900 Phase 2 enrolling.","Company reallocated resources to focus on late-stage CNS programs; delayed PTSD study in Kenya and reduced COVID-19 investment."],"urls":{"canonical":"https://secwatch.observer/filing/0001387131-23-006126","json":"https://secwatch.observer/filing/0001387131-23-006126.json","markdown":"https://secwatch.observer/filing/0001387131-23-006126.md","text":"https://secwatch.observer/filing/0001387131-23-006126.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000138713123006126/0001387131-23-006126-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000138713123006126/tnxp_8k-050823.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T12:42:29.172132+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"14ccac0ca09dfcccf9cd29f9f43fd2dd58d8f465","claim":"Tonix Pharmaceuticals Holding Corp. reported financial results for first quarter ended March 31, 2023.","evidence_excerpt":"On May 8, 2023, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced its operating results for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1430306/000138713123006126/0001387131-23-006126-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}